GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant.
High growth potential with adequate balance sheet.
Share Price & News
How has GW Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GWPH's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GWPH underperformed the US Pharmaceuticals industry which returned -0.3% over the past year.
Return vs Market: GWPH underperformed the US Market which returned 4.8% over the past year.
Price Volatility Vs. Market
How volatile is GW Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StGW Pharmaceuticals plc (NASDAQ:GWPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
1 month ago | Simply Wall StWhat Type Of Shareholder Owns GW Pharmaceuticals plc's (NASDAQ:GWPH)?
1 month ago | Simply Wall StDoes GW Pharmaceuticals plc's (NASDAQ:GWPH) CEO Pay Compare Well With Peers?
Is GW Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GWPH ($125.35) is trading below our estimate of fair value ($591.01)
Significantly Below Fair Value: GWPH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GWPH is poor value based on its PE Ratio (117.7x) compared to the Pharmaceuticals industry average (20.7x).
PE vs Market: GWPH is poor value based on its PE Ratio (117.7x) compared to the US market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: GWPH is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: GWPH is overvalued based on its PB Ratio (5.4x) compared to the US Pharmaceuticals industry average (3.3x).
How is GW Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GWPH's forecast earnings growth (61% per year) is above the savings rate (2.2%).
Earnings vs Market: GWPH's earnings (61% per year) are forecast to grow faster than the US market (22.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GWPH's revenue (26.3% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: GWPH's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GWPH's Return on Equity is forecast to be low in 3 years time (16.6%).
How has GW Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GWPH has a high level of non-cash earnings.
Growing Profit Margin: GWPH became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: GWPH has become profitable over the past 5 years, growing earnings by -11.4% per year.
Accelerating Growth: GWPH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GWPH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).
Return on Equity
High ROE: GWPH's Return on Equity (4.6%) is considered low.
How is GW Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: GWPH's short term assets ($672.7M) exceed its short term liabilities ($103.5M).
Long Term Liabilities: GWPH's short term assets ($672.7M) exceed its long term liabilities ($35.9M).
Debt to Equity History and Analysis
Debt Level: GWPH's debt to equity ratio (1.3%) is considered satisfactory.
Reducing Debt: GWPH's debt to equity ratio has reduced from 5.6% to 1.3% over the past 5 years.
Debt Coverage: GWPH's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if GWPH's interest payments on its debt are well covered by EBIT.
What is GW Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GWPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GWPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GWPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GWPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GWPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Justin Gover (49yo)
Mr. Justin D. Gover, BSc, MBA has been the Chief Executive Officer of GW Pharmaceuticals PLC since January 1999. Mr. Gover is responsible for managing GW Pharmaceuticals’s operations, equity financing and ...
CEO Compensation Analysis
Compensation vs Market: Justin's total compensation ($USD7.86M) is above average for companies of similar size in the US market ($USD5.84M).
Compensation vs Earnings: Justin's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||21.5yrs||US$7.86m||0.70% $27.2m|
|Chief Financial Officer||3.33yrs||US$2.73m||0.033% $1.3m|
|Chief Legal Officer||3yrs||US$2.89m||0.0026% $102.5k|
|Chief Medical Officer||3.17yrs||US$3.00m||0.021% $809.9k|
|Chief Operating Officer||7.75yrs||US$763.06k||0.00067% $26.1k|
|Vice President of Investor Relations||7.33yrs||no data||no data|
|Chief Human Resources Officer||1yr||no data||no data|
|Head of Discovery Research||3.17yrs||no data||no data|
|U.S. Chief Commercial Officer||1.25yrs||no data||0.018% $696.5k|
|MD of UK & Company Secretary||13.5yrs||US$705.86k||0.010% $393.1k|
Experienced Management: GWPH's management team is considered experienced (3.3 years average tenure).
|CEO & Executive Director||21.5yrs||US$7.86m||0.70% $27.2m|
|Independent Director||7.42yrs||US$374.84k||0.0019% $75.2k|
|Independent Deputy Chairman & Senior Independent Director||13.5yrs||US$372.77k||0.0074% $287.5k|
|Founder & Executive Chairman||22.5yrs||US$3.92m||1.51% $58.8m|
|Independent Director||2.58yrs||US$345.77k||no data|
|Independent Director||2.58yrs||US$357.82k||0.0018% $68.2k|
|Independent Director||2.58yrs||US$349.96k||0.0018% $68.6k|
Experienced Board: GWPH's board of directors are considered experienced (7.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
GW Pharmaceuticals plc's company bio, employee growth, exchange listings and data sources
- Name: GW Pharmaceuticals plc
- Ticker: GWPH
- Exchange: NasdaqGM
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.895b
- Shares outstanding: 31.08m
- Website: https://www.gwpharm.com
Number of Employees
- GW Pharmaceuticals plc
- Sovereign House
- Vision Park
- CB24 9BZ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GWPR.F||OTCPK (Pink Sheets LLC)||Ordinary Shares||US||USD||Jun 2001|
|GWPH||NasdaqGM (Nasdaq Global Market)||Yes||ADS EA REPR 12 ORD GBP0.00||US||USD||May 2013|
|GW2A||DB (Deutsche Boerse AG)||Yes||ADS EA REPR 12 ORD GBP0.00||DE||EUR||May 2013|
|0IT7||LSE (London Stock Exchange)||Yes||ADS EA REPR 12 ORD GBP0.00||GB||USD||May 2013|
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/02 23:55|
|End of Day Share Price||2020/07/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.